Abstract 292P
Background
Shared decision making (SDM) is a dynamic clinical process where physicians and patients mutually and actively share information and collaborate to discuss available evidence during treatment decisions, and where patients are supported to consider options in order to achieve informed preferences. It has become a hallmark of patient-centered care and communication which highlights physician-patient relationship as the core in improving health outcomes, and refers to the type of care that is responsive to the individual needs and preferences of the patient, ensuring that clinical decisions are aligned with his or her values. In cancer care, preference-sensitive decisions range from screening decisions, to treatment decisions, and to end-of-life care. There is little experience with SDM in the Philippines and its integration into the practice of Oncology. The objective of this study was to explore patient perception and evaluate the extent to which a shared decision-making process is implemented in clinical encounters at the Cancer Institute adult outpatient clinics of the Philippine General Hospital.
Methods
The SDM Q-9 Filipino version was administered to 267 patients who were consulting at the adult outpatient clinics of the Cancer Institute over one month.
Results
More than 90% of the patients surveyed agreed that shared decision-making process were being practiced at the Cancer Institute adult outpatient clinics. Of these, almost half of the respondents answered “somewhat agreed” in all items, except for the domain which sought if the physician helped the patient to understand information which showed stronger trend towards agreement. Notably, the domains involving identification of preferences and shared decision showed weaker trend towards agreement, with 5% and 7% of patients surveyed disagreeing that these steps were being observed in practice, respectively. This indicated that among the nine items of the SDM Q-9, these areas required the most strengthening.
Conclusions
In this study, the investigators observed that cancer patients agreed that shared decision making was being practiced during their clinical encounters with their respective physicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session